Sol-Gel Technologies 将来の成長

Future 基準チェック /26

Sol-Gel Technologiesは、26.7%と27.7%でそれぞれ年率26.7%で利益と収益が成長すると予測される一方、EPSはgrowで30.5%年率。

主要情報

26.7%

収益成長率

30.5%

EPS成長率

Pharmaceuticals 収益成長	21.5%
収益成長率	27.7%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	15 Nov 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

DB:4SG - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	10	-10	-10	N/A	1
12/31/2025	8	-14	-9	N/A	2
12/31/2024	13	-8	-4	N/A	1
9/30/2024	12	-10	N/A	N/A	N/A
6/30/2024	7	-15	-17	-17	N/A
3/31/2024	2	-23	N/A	N/A	N/A
12/31/2023	2	-27	-18	-18	N/A
9/30/2023	1	-28	N/A	N/A	N/A
6/30/2023	1	-26	-11	-11	N/A
3/31/2023	5	-20	N/A	N/A	N/A
12/31/2022	4	-15	-10	-9	N/A
9/30/2022	25	5	N/A	N/A	N/A
6/30/2022	33	10	-3	-3	N/A
3/31/2022	31	2	N/A	N/A	N/A
12/31/2021	31	3	-8	-8	N/A
9/30/2021	13	-17	N/A	N/A	N/A
6/30/2021	6	-27	-27	-27	N/A
3/31/2021	6	-26	N/A	N/A	N/A
12/31/2020	9	-29	-26	-25	N/A
9/30/2020	11	-29	N/A	N/A	N/A
6/30/2020	13	-28	-20	-19	N/A
3/31/2020	20	-26	N/A	N/A	N/A
12/31/2019	23	-25	-23	-22	N/A
9/30/2019	19	-30	N/A	N/A	N/A
6/30/2019	14	-30	-29	-28	N/A
3/31/2019	6	-32	N/A	N/A	N/A
12/31/2018	0	-32	-25	-23	N/A
9/30/2018	0	-26	N/A	N/A	N/A
6/30/2018	0	-32	N/A	-21	N/A
3/31/2018	0	-32	N/A	N/A	N/A
12/31/2017	0	-32	N/A	-24	N/A
9/30/2017	N/A	-31	N/A	-22	N/A
6/30/2017	N/A	-24	N/A	-22	N/A
3/31/2017	N/A	-22	N/A	N/A	N/A
12/31/2016	N/A	-21	N/A	-18	N/A
12/31/2015	N/A	-10	N/A	-8	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 4SG今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: 4SG今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: 4SG今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: 4SGの収益 ( 27.7% ) German市場 ( 5.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: 4SGの収益 ( 27.7% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 4SGの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Sol-Gel Technologies 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Forecast to breakeven in 2021

Forecast breakeven pushed back to 2024

Recent updates

Sol-Gel Technologies Receives 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement

Third quarter 2024 earnings released: US$0.013 loss per share (vs US$0.20 loss in 3Q 2023)

Second quarter 2024 earnings released: EPS: US$0.071 (vs US$0.22 loss in 2Q 2023)

Sol-Gel Technologies Ltd., Annual General Meeting, Aug 27, 2024

Sol-Gel Technologies Ltd. Announces Alon Seri-Levy Step Downs from His Position as CEO, Effective December 31, 2024

First quarter 2024 earnings released: US$0.23 loss per share (vs US$0.41 loss in 1Q 2023)

New major risk - Revenue and earnings growth

Full year 2023 earnings released: US$1.01 loss per share (vs US$0.65 loss in FY 2022)

Sol-Gel Technologies Ltd. Announces Resignation of Shmuel Ben Zvi from Board

Third quarter 2023 earnings released: US$0.20 loss per share (vs US$0.15 loss in 3Q 2022)

Second quarter 2023 earnings released: US$0.22 loss per share (vs US$0.006 loss in 2Q 2022)

Sol-Gel Technologies Ltd. Appoints Sharon Kochan to the Board of Directors

Sol-Gel Technologies Ltd., Annual General Meeting, Jul 26, 2023

First quarter 2023 earnings released: US$0.41 loss per share (vs US$0.24 loss in 1Q 2022)

Full year 2022 earnings released: US$0.65 loss per share (vs US$0.14 profit in FY 2021)

Investor sentiment deteriorates as stock falls 17%

Investor sentiment improves as stock rises 21%

Third quarter 2022 earnings released: US$0.15 loss per share (vs US$0.056 profit in 3Q 2021)

Insufficient new directors

Insufficient new directors

Second quarter 2022 earnings released: US$0.006 loss per share (vs US$0.35 loss in 2Q 2021)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Insufficient new directors

Sol-Gel Technologies Announces FDA Approval of EPSOLAY

Sol-Gel Technologies Announces the Commercial Availability of TWYNEO

Sol-Gel Technologies Ltd., Annual General Meeting, May 19, 2022

Full year 2021 earnings released: EPS: US$0.14 (vs US$1.30 loss in FY 2020)

Forecast to breakeven in 2021

Sol-Gel Technologies Announces Positive Update Related to FDA Review Status of EPSOLAY®

Third quarter 2021 earnings released: EPS US$0.056 (vs US$0.38 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.35 loss per share (vs US$0.31 loss in 2Q 2020)

First quarter 2021 earnings released: US$0.18 loss per share (vs US$0.33 loss in 1Q 2020)

Forecast breakeven pushed back to 2024

Sol-Gel Technologies Provides Update on FDA Review of Epsolay®

Full year 2020 earnings released: US$1.30 loss per share (vs US$1.26 loss in FY 2019)

Revenue beats expectations

New 90-day high: €8.70

New 90-day high: €8.25

Sol-Gel Technologies, Ltd Announces FDA Acceptance for Filing of New Drug Application for Twyneo for the Treatment of Acne Vulgaris

New 90-day high: €7.55

Revenue beats expectations

New 90-day high: €7.10

Third quarter 2020 earnings released: US$0.38 loss per share

Sol-Gel Technologies Ltd. to Report Q3, 2020 Results on Nov 12, 2020

New 90-day low: €5.80

New 90-day low - €6.60

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘